

The Pharmacotherapy Preparatory Review & Recertification Course Pediatrics Kirsten H. Ohler, PharmD, BCPS University of Illinois at Chicago

Conflict of Interest Disclosure

 The speaker, Kirsten Ohler, has no real or potential conflicts of interest related to the subject matter in this presentation.

Agenda

Discuss the pharmacological management of the following pediatric disease states:

- Pediatric and neonatal sepsis/meningitis
- Respiratory syncytial virus (RSV)
- Otitis media
- Immunizations
- Pediatric seizure disorders
- Attention deficit hyperactivity disorder (ADHD)

Case 1

Neonate born at 36 week's gestational age develops respiratory distress, hypotension, and mottling at 5 hours of life. Witnessed seizure in the NICU. Mother is GBS positive; three doses of penicillin given before delivery

Best empiric antibiotic regimen?

- a. Ampicillin + gentamicin
- b. Cefuroxime
- c. Ceftriaxone + vancomycin
- d. Rifampin

Sepsis/Meningitis - Pathogens

<u>Age</u> 0 - 1 month	<u>Organism</u> Group B β Streptococcus, E. coli, Listeria, viral, nosocomial
1 - 3 months	Neonatal pathogens, H. influenzae, N. meningitidis, Strep pneumoniae
3 mo - 12 yr	H. influenzae, N. meningitidis, Strep pneumoniae
> 12 yr	N. meningitidis, Strep pneumoniae
	Page 1- 5

Case 1

Neonate born at 36 week's gestational age develops respiratory distress, hypotension, and mottling at 5 hours of life. Witnessed seizure in the NICU. Mother is GBS positive; three doses of penicillin given before delivery.

Best empiric antibiotic regimen?

- 🕨 a. Vancomycin
 - b. Ampicillin + gentamicin
 - c. Ampicillin + ceftriaxone
 - d. Ceftazidime + gentamicin

Page 1-5

Case 2

Culture results reveal gram negative rods in the cerebral spinal fluid.

Which recommendation regarding antibiotic prophylaxis is best?

- a. 5-month old stepsister is at high risk and should receive rifampin
- b. The patient should receive rifampin to eliminate nasal carriage
- c. Antibiotic prophylaxis is not indicated
- d. All close contacts should receive rifampin

Chemoprophylaxis

- Purpose: prevent the spread of Haemophilus influenzae and Neisseria meningitidis
- High risk groups: household contacts, nursery or child care center contacts, direct contact with patient's secretions
- Drug of choice: rifampin

Page 1-6

Case 2 Culture results reveal gram negative rods in the cerebral spinal fluid. Which recommendation regarding antibiotic prophylaxis is best? a. 5-month old stepsister is at high risk and should receive rifampin b. The patient should receive rifampin to eliminate nasal carriage c. Antibiotic prophylaxis is not indicated d. All close contacts should receive rifampin

d. All close contacts should receive rifampin Page 1-6

Case 3

6-year-old boy presents to the ED with fever, altered mental status & petechiae. No trauma. Tox screen negative. Elevated WBC with a left shift. Cultures are pending.

Best empiric antibiotic regimen?

- a. Ampicillin + gentamicin
- b. Cefuroxime
- c. Ceftriaxone + vancomycin
- d. Rifampin

Page 1-6

Age Organism 0 - 1 month Group B β Streptococcus, E. coli, Listeria, viral, nosocomial 1 - 3 months Neonatal pathogens, H. influenzae, N. meningitidis, Strep pneumoniae 3 mo - 12 yr H. influenzae, N. meningitidis, Strep pneumoniae > 12 yr N. meningitidis, Strep pneumoniae

Page 1-5

Case 3

6-year-old boy presents to the ED with fever, altered mental status & petechiae. No trauma. Tox screen negative. Elevated WBC with a left shift. Cultures are pending.

Best empiric antibiotic regimen?

- a. Ampicillin + gentamicin
 b. Cefuroxime
- c. Ceftriaxone + vancomycin

d. Rifampin


Case 4

You are screening babies during RSV season for risk factors associated with the development of severe RSV infection.

Which of the following is the best recommendation to make regarding the use of palivizumab for RSV prophylaxis?

Page 1-7

Case 4 Palivizumab should <u>NOT</u> be prescribed for: a. A 34 weeks' gestation baby with a cyanotic congenital heart defect b. A 21-day-old, 31 weeks' gestation baby, only child, non-smoking parents, will not attend day care c. A 5-month-old, 29 weeks' gestation infant, history of CLD, no O₂ or meds d. An 18-month-old, 26 weeks' gestation infant




Respiratory Syncytial Virus

- AAP recommendations for prophylaxis
 - □ infants born < 32 weeks who are ≤ 6 mo at the beginning of RSV season</p>

history of CLD, no O2 or meds in past 8 mo

- infants with CLD who are < 2 yo and require medical management of CLD w/in last 6 months
- □ infants between 32 34 weeks, 6 days gestation who are ≤ 3 mo at the beginning of RSV season with risk factors may benefit
- □ infants ≤ 24 months of age with hemodynamically significant congenital heart disease Page 1-8



Case 5

18-month-old with history of premature birth and CLD is admitted to the PICU with respiratory distress requiring intubation, fever, and a 3-day history of cold-like symptoms. A nasal swab is positive for respiratory syncytial virus.

Case 5

Which is the best intervention?

- 🕨 a. Palivizumab
- b. Corticosteroids
- c. Cefuroxime
- d. Intravenous fluids and supportive care


Case 6

A 5-month-old infant, born at term, healthy is treated for her first case of otitis media with amoxicillin 45 mg/kg/day for 7 days. Follow-up exam shows fullness of middle ear, cloudy TM. Afebrile and eating well.

Best treatment recommendation?

- a. No antibiotics are warranted at this time
- b. High-dose (90 mg/kg/day) amoxicillin x 7 days
- c. Decongestant & antihistamine daily
- d. Azithromycin

Page 1-10




Case 6

A 5-month-old infant, born at term, healthy is treated for her first case of otitis media with amoxicillin 45 mg/kg/day for 7 days. Follow-up exam shows fullness of middle ear, cloudy TM. Afebrile and eating well.

Best treatment recommendation?

- a. No antibiotics are warranted at this time
- b. High-dose (90 mg/kg/day) amoxicillin x 7 days
- c. Decongestant & antihistamine daily
- d. Azithromycin

Page 1-10



d. No antibiotic therapy is warranted

Case 8

1-year-old boy with history of Kawasaki disease treated 4 months ago with IVIG. At well-child check-up, due for MMR and varicella. Mother has several concerns regarding immunizations.

Best reason to defer administration of vaccines? a. Association between MMR & autism

- b. Allergic reaction to MMR if patient has egg allergy
- c. Many concurrent vaccines can overload immune system
- d. Decreased vaccine efficacy because of previous IVIG administration Page 1-11

Immunizations

- Barriers to routine immunization contraindications
 - anaphylactic reaction to the vaccine
 - acute moderate severe febrile illness
 - immunodeficiency, pregnancy, recent IVIG
 - encephalopathy w/in 7 days of previous DTaP

misconceptions regarding contraindications

mild acute illness, current antibiotics, etc.

Page 1-13

Immunizations Special populations Preterm infants immunize based on chronologic age Immunocompromised children no live vaccines Patients receiving corticosteroids recommendations depend on steroid dose / duration Patients who recently received IVIG affects live vaccines (ex. MMR, varicella) recommendations depend on indication / dose of IVIG HIV-infected patients recommendations depend on degree of immunocompromise Page 1-14




1-year-old boy with history of Kawasaki disease treated 4 months ago with IVIG. At well-child check-up, due for MMR and varicella. Mother has several concerns regarding immunizations.

Best reason to defer administration of vaccines?

- a. Association between MMR & autism
 - b. Allergic reaction to MMR if patient has egg allergy
 - c. Many concurrent vaccines can overload immune system
- d. Decreased vaccine efficacy because of previous IVIG administration Page 1-11

Case 9 For which of the following patients would it be best to recommend deferring immunizations? a. 12-month-old boy who recently completed a cycle chemotherapy for ALL b. 6-month-old girl on amoxicillin for otitis media c. 12-month-old, HIV-positive boy with CD4 >1000 d. 12-year-old girl completing a prednisone

"burst" (1 mg/kg/day) for asthma exacerbation Page 1-14



chedule (Figure 3))				*				'	_	fall behind			
		1	2	4		9	12			19-23			
Vaccine V 🛛 Age 🕨	Birth	month	months	months	nonths	montins	months	months	months	months	years	years	Range of
Hepatits B'	Hep B	He	pB				НерВ						examed scentral
Rotevirus'			RV	RV	R₩								dige
Diphtheria, tetanus, pertussis ^a			DTaP	DTaP	DīaP		see bohole"	וס	a?			DTaP	
Haemophilus influenzae type b'			Hib	Hib	Hib'		H	ib					fance di
Pheumococcař			PCV	PCV	PCV		P	X			Př	SV 🛛	econnect spector set
inactivated poliovirus ¹			PV	IPV			IPV					IPV	hgh tek groups
influenza ⁷								Influenz	a (Yearly)				111
Neasles, mumps, rubella ^y							M	/R		sec bahale"		MMR	(///
Varicella ^r							Vario	cella		see bahdit ^a		Varicelia	Range of examined
Hepatitis A ^{ra}								Dos	e1º		/HepÅ	Series//	chiber and estamligh
Neniroccocca/*								NCV4	- see foo	tnote"			ist grups

Vaccine V	Age⊮	7-10 years	11-12 years	13-18 years	
Tetanus, diphtheri	ia, pertussis ¹	1 dose (if indicated)	1 dose	1 dose (if indicated)	Range of recomme
Human papilloma	winus ²	See footnote ²	3 doses	Complete 3-dase series	agestoral children
Meningococcal ⁸		See faatn ote ³	Dose 1	Boosterat age 16 yea	5
Influenza ⁴			Influenza (yearly)		
Pheumococcal ⁵			See footnote ⁵		large of
Hepatitis A ⁶			Complete 2-dose series		ages for ca
Hepatitis B'			Complete 3-dose series		
Inactivated policy	rirus ⁸		Complete 3-dose series		
Measles, mumps, i	rubella ⁹		Complete 2-dose series		Rapped
Varicella ¹⁰			Complete 2+dose series		ages for ce high rest of

Immunizations Special populations Preterm infants immunize based on chronologic age Immunocompromised children no live vaccines Patients receiving corticosteroids recommendations depend on steroid dose / duration Patients who recently received IVIG affects live vaccines (ex. MMR, varicella) recommendations depend on indication / dose of IVIG HIV-infected patients recommendations depend on degree of

immunocompromise Pages 1-14 & 1-15

Case 9

For which of the following patients would it be best to recommend deferring immunizations?

- a. 12-month-old boy who recently completed a cycle chemotherapy for ALL
- b. 6-month-old girl on amoxicillin for otitis media
- c. 12-month-old, HIV-positive boy with CD4 >1000
- d. 12-year-old girl completing a prednisone "burst" (1 mg/kg/day) for asthma exacerbation Page 1-14

Case 10 14-year-old moderately obese girl complains of oxcarbazepine three weeks ago for partial seizures. Sexually active + contraception. a. Change to carbamazepine




erythematous pruritic rash. She was started on


Which of the following is the best intervention?


- b. Change to levetiracetam
- c. Change to valproic acid
- d. No change in therapy is necessary


Seizure type	Drugs of Choice	Alternatives
Partial	VPA, CBZ, PHT	PB, Gabapentin, Lamotrigine, Tiagabine, Topiramate, Oxcarbazepine, Zonisamide, Levetiracetam
Generalized		
Tonic-clonic	VPA, CBZ, PHT	Lamotrigine, Topiramate, Zonisamide, Levetiracetam
Myoclonic	VPA	Topiramate, Zonisamide, Levetiracetam
Absence	Ethosuximide, VPA	Lamotrigine, Zonisamide, Levetiracetam
Lennox-Gastaut	VPA, Topiramate, Lamotrigine	Felbamate, Zonisamide
Infantile spasms	ACTH	Lamotrigine, tiagabine, topiramate, VPA, zonisamide


Pediatric Seizures	
Rash• Carbamazepine• Oxcarbazepine• Lamotrigine• Phenytoin• Phenobarbital• ZonisamideMenstrual irregularities• Valproic acid	 Weight gain Valproic acid Gabapentin Weight loss Topiramate Zonisamide Cognitive/CNS effects Phenobarbital Topiramate Levetiracetam














Case 12 The patient is started on methylphenidate OROS (Concerta®); symptoms well-controlled, but complaining of insomnia. Best modification to treatment regimen?

- a. Administer Concerta later in dayb. Change to methylphenidate modified
- release (Metadate CD) once a day.
- d. Change to atomoxetine at bedtime

Page 1-22

2012 Updates in Therapeutics:

The Pharmacotherapy Preparatory Review and Recertification Course

Geriatrics


Jennifer Dugan, PharmD, BCPS Kaiser Permanente Colorado

Conflict of Interest Disclosure

Questions

 The speaker, Jennifer Dugan, has no real or potential conflicts of interest related to the subject matter in this presentation.

Patient Case 1 Patient Case # 1cont. Which of the following functional assessments NH is an 85 yo woman in a nursing facility. is most important? Type 2 DM, HTN, moderate dementia due to A. IADLS CVA, s/p hip fracture. B. Assessment for depression Glyburide 10 mg/d, lisinopril 10 mg/d, metformin 500 mg BID, donepezil 10 mg/d, C. Assessment for gait and balance aspirin 81 mg/d, MVI, zolpidem 5 mg QHS PRN, Meclizine 12.5 mg TID PRN, bowel D. Assessment for pressure sores regimen Handout Page 1-39; Answer Page 1-64 Handout Page 1-39; Answer Page 1-64




Physiologic Changes in the Elderly Pearls

- Absorption from transdermal patches may be reduced if insufficient subcutaneous fat
- Distribution may be increased for highly protein-bound meds
- Metabolism impacts benzodiazepine choices
- Elimination is not just about Serum Creatinine

Patient Case # 3

Based on your assessment of age- and diseaserelated changes in N.H., which one of the following areas of pharmacotherapy is best to

address first?




- B. Alzheimer disease treatment
- C. Hypertension treatment
- D. Stroke prevention

Handout Page 1-39; Answer Page 1-64


N.H. meds

- Glyburide 10 mg/day
- Lisinopril 10 mg/day
- Metformin 500 mg BID
- Donepezil 10 mg/day
- Aspirin 81 mg/day
- MVI




Common Drug Related Problems in Elderly

- Overuse
- Underuse
 - ACE inhibitors in CHF, anticoagulation in A fib, drug therapy post MI, untreated depression
- Medication Adherence
 Intentional nonadherence related to perceived overmedication, ADRs, cost
- Use of inappropriate medications
- Adverse drug events




Potentially Inappropriate Medications

- Common offenders
 - Diphenhydramine
 - Long Acting Benzos (Diazepam, Chlordiazepoxide)
 - Skeletal Muscle Relaxants
 - Amitriptyline, Doxepin, Imipramine
 - GI antispasmodics and other anticholinergics
 - Indomethacin, Piroxicam
 - Promethazine
 - Butalbital compounds
 - Proposyphene




Treating Adverse Effects with New Med

- Watch for prescribing cascade:
 - $\hfill\square$ Metoclopramide ${\rightarrow} \textsc{Parkinsonian}$ sxs ${\rightarrow}$ Levodopa
 - $\ \ \, \square \ \, \text{Donepezil} \rightarrow \text{Incontinence} \rightarrow \text{Oxybutynin}$
 - □ Diphenhydramine \rightarrow Urinary Retention \rightarrow Terazosin
 - $\Box \text{ Dihydropyridine CCB} \rightarrow \text{Edema} \rightarrow \text{Furosemide}$



vers 9.5 mg/day. Handout Page 1-44; Answer Page 1-64

Symptoms of Dementia • Functional disability • Cognitive impairments • Behavioral and psychological symptoms



Differentiating Dementias	
Diagnosis	Key Symptoms
Dementia with Lewy bodies	Visual hallucinations, Parkinsonian sx, fluctuating alertness
Vascular Dementia	Acute onset, stepwise deterioration, focal neurologic signs
Alzheimer's Disease	Slow onset, progressive decline

Delirium

- Disturbance of consciousness and difficulty with attention
- Change in cognition (eg, memory deficit, disorientation, language disturbance, perceptual disturbance)
- The disturbance develops over a short period (usually hours to days) and tends to fluctuate during the course of the day.
- Evidence from the history, physical examination, or laboratory findings is present that indicates the disturbance is caused by a direct physiologic consequence of a general medical condition, an intoxicating substance, medication use, or more than one cause.

Adapted from: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Association; 2000.

Therapy for Dementia

- Acetylcholinesterase Inhibitors
 - Donepezil
 - Galantamine
- Rivastigmine
- Memantine
- Efficacy and Safety Pearls

GI effects from AChEIs

	Donepezil	Galantamine	Rivastigmine po	Rivastigmine patch
Nausea	19%	24%	47%	7%
Vomiting	8%	13%	31%	6%
Diarrhea	15%	12%	19%	6%

Patient Case # 7 RA is 75 yo woman with Alzheimer disease on donepezil 10 mg/day for 3 years. MMSE $21/30 \rightarrow 17/30$. RA is at home with husband- can't do IADLs but can do ADLs with cueing.

Which one of the following is the best course of action?

A. Change her treatment from donepezil to rivastigmine.

B. Stop donepezil.

C. Add memantine 5 mg/day.

D. Add vitamin E 400 units 2 times/day.

Handout Page 1-45; Answer Page 1-64

Evaluating Efficacy

- Evaluate patient in 3-6 months to determine need for continued treatment
- Utilize caregiver reports, MMSE/SLUMS, and/or ADLs
- No change or mild improvement at 6 months→continue treatment
- Continued decline on therapy → consider discontinuation or changing medication
- 4 points/year is average decline without treatment


Patient Case # 8

87-yo woman in dementia unit. PMH: AD, PD, OA, requiring total assistance with bathing and dressing and help with feeding. Meds: donepezil 10 mg/day, memantine 10 mg 2 times/day, carbidopa/levodopa 25/100 mg 4 times/day, oxybutynin extended release 5 mg/day, and MVI. MMSE score is 5/30, and GDS is 4/15. Patient crying out "Help me, help me." Which one of the following additional assessment tools is most necessary in assessing this patient? **A. Brief Psychiatric Rating Scale**

B. Functional Assessment Staging

C. An evaluation of incontinence

D. Framingham Risk Assessment Handout Page 1-48; Answer Page 1-64



Patient Case # 10

This same patient (MMSE 5/30, GDS 4/15) is medically assessed, and reversible causes of her hyper-vocalization are ruled out. Which one of the following represents the best approach to treating her behavioral symptoms? A. Implement a behavioral approach

B. Add valproic acid

- C. Add quetiapine
- D. Add citalopram
 - Handout Page 1-48; Answer Page 1-65

General Approach to Behaviors in Dementia

- Define target agitated behavior
- Consider contributing causes
- Address ALL causes
- Non-pharmacologic measures
- Pharmacologic interventions

Lyketsos et al, Am J Geriatr Psychiatry July 2006;14:7

	ples of Non-pha ventions	rmacologic
Behavior	Causes	Management
Agitation	Discomfort, pain	Assess/manage pain, constipation, infection
I	Physical illness (UTI)	Evaluate medically, treat
	Overstimulation-noise, TV, people, etc	Reduce noise, stress; limit TV, crowding
Paranoia	Forgot where placed object	Offer to help find; have more than one of same object
	Misinterpreting actions or words	Do not argue or try to reason, do not take personally, distract
1	Change in environment	Familiarize, reassure, set routine
Insomnia	Depression	Treat with antidepressant
1	Less need for sleep	Later bedtime, more exercise

Adapted from Sutor B et al. Mayo Clin Proc. 2001;76:540-550

When should we consider pharmacologic treatment of BPSD?

 Behavior is dangerous, distressing, damaging to social relationships and persistent

AND

 Has not responded to comprehensive nonpharmacologic treatment plan, including removal of possibly offending drugs

OR

 Requires emergency treatment to allow proper investigation of underlying problems

Pharmacologic Treatment


- Cochrane review suggests best evidence is with risperidone and olanzapine for psychosis and aggression
- Start at low doses
- Use quetiapine if patient has comorbid Parkinson's disease or Lewy Body Dementia
- Use for shortest duration possible
- Adverse effects include increased mortality; recent cohort study* suggests worse with haloperidol, less with quetiapine


*BMJ 2012;344:e977

Patient Case #11


A 75-year-old woman reports urinary urgency, frequency, and loss of urine when she cannot make it to the bathroom in time. She wears a pad at night that she changes 2 or 3 times. PMH: Alzheimer disease (MMSE 23), osteoarthritis, and hypothyroidism.


UA negative, exam WNL, PVR normal.





Handout Page 1-53; Answer Page 1-65





Types of Urinary Incontinence

- Functional
- Urge (Bladder overactivity)
- Stress (Urethral underactivity)
- Overflow (Urethral overactivity/Bladder underactivity)
- Mixed

Nonpharmacologic Interventions

- Pelvic floor exercises (Kegel exercises)
- Bladder training
- Biofeedback
- Scheduled/Timed Voiding
- Avoid aspartame, spicy/citrus foods, caffeine, carbonated beverages
- Pessaries/bladder neck support prostheses


Treatment of UI

- Functional
 - Assist with functional disabilities
 - Scheduled bathroom visits
 - Bedside commode
 - Stop precipitating drugs
- Urge
 - Nonpharmacologic interventions
 - Anticholinergics (generally equivalent efficacy)

Anticholinergic Adverse Effects

Drug	Dry mouth %	Constipation %	Dizziness%
Oxybutynin	88	32	38
Oxy ER/XL	68	9	11
Oxy TDS	10	5	4
Oxy gel	8	1	3
Tolterodine	50, 39	10, 10	4, 3
Fesoterodine	99	14	2
Trospium	33	11	?
Solifenacin	34	19	1
Darifenacin	59	28	0

Treatment of overactive bladder in women. AHRQ Publication No. 09-E017. 8/09




Patient Case #13 WF is an 85-year-old man with pain from hip OA. He also has hypertension, coronary artery disease, and BPH. For his OA, W.F. has been taking acetaminophen 650 mg 3 times/day. W.F. reports that acetaminophen helps, but he still experiences pain that limits his ability to Alpha Blockers walk. Which of the following interventions would be best? Alpha Reductase Inhibitors Combination Therapy A. Change the analgesic to celecoxib May be needed in men with LUTS, a larger B. Add hydrocodone prostate size (>40g), and an elevated PSA C. Change the analgesic to ibuprofen D. Add glucosamine Handout Page 1-58; Answer Page 1-65

Osteoarthritis

BPH

- Nonpharmacologic Treatment
- Acetaminophen dosing
- NSAIDs vs Opioids
- Preventing adverse effects
- Glucosamine




Rheumatoid Arthritis

- DMARDs first line
 - □ MTX
 - Hydroxychloroquine
 - Sulfasalazine
 - □ Leflunomide
- Biologic Treatments
- NSAIDs and Corticosteroids
 - Short term
 - No effect on disease progression

Questions

?????



The Pharmacotherapy Preparatory Course Gastrointestinal Disorders Brian A. Hemstreet, Pharm.D., BCPS University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Conflict of Interest Disclosures

Dr. Hemstreet has conducted research sponsored by Astra Zeneca.

Learning Objectives

- 1. Review and apply national guideline treatment strategies for the following gastrointestinal (GI) disorders: gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, viral hepatitis, chronic liver disease, upper GI bleeding, constipation, diarrhea, irritable bowel syndrome (IBS), nausea, vomiting, pancreatitis, prevention of stress related mucosal disease (SRMD).
- 2. Recommend appropriate pharmacologic and nonpharmacologic interventions for the treatment of GERD.
- 3. Differentiate between clinical signs, symptoms, risk factors, and treatment of both *Helicobacter pylori* and nonsteroidal anti-inflammatory drug (NSAID)-associated PUD.

Learning Objectives

- 4. Discuss the role of pharmacologic intervention in the treatment of nonvariceal upper GI bleeding.
- 5. Review the clinical differences in signs, symptoms, and treatment of Crohn's disease and ulcerative colitis.
- 6. Identify the common manifestations of chronic liver disease and their treatment.
- 7. Review the treatment of both acute and chronic viral hepatitis.

Learning Objectives

- 8. Recognize pertinent information for educating patients and prescribers regarding the appropriate use of pharmacologic agents for various GI disorders.
- 9. Recommend appropriate pharmacologic and nonpharmacologic interventions for diarrhea and constipation.
- 10. Review recommendations for the treatment and prevention of nausea and vomiting.

Learning Objectives

- 11. Discuss the clinical and treatment differences between acute and chronic pancreatitis.
- 12. Discuss the role of pharmacologic intervention in the treatment of IBS.
- 13. Understand commonly encountered statistical tests and concepts using GI disorders as examples.

Patient Case # 1

- HPI: 55 year old man with 8 month history of GERD symptoms 4-5 days/week. Prescriber wishes to initiate esomeprazole 20 mg/day.
- PMH: GERD, MI, HF, Hypothyroidism
- MEDS: Ranitidine + Calcium Carbonate, Metoprolol, Furosemide, Lisinopril, Aspirin

Handout Page 1-81; Answer Page 1-137

Patient Case # 1

- Which one of the following baseline tests is best to perform in this patient today before initiating his esomeprazole therapy?
- A. Peripheral bone mineral density screening.
- B. Serum magnesium.
- C. Serum potassium.
- D. Chest radiograph.

Handout Page 1-81; Answer Page 1-137

Treatment of GERD

- Nonpharmacologic/Lifestyle modifications
 Targeted
- Antacids
- Acid suppression (as needed or scheduled)
- Proton Pump Inhibitors
- Histamine-2 Receptor Antagonists
- Promotility Agents
- Proper patient education
- Surgical intervention

PPI Safety Concerns

Adverse Effect	Prevention and Management		
Risk of Fracture (Hip, wrist, spine)	Re-evaluate need Limit dose and duration Ensuring adequate Calcium and Vitamin D BMD screening if at risk for low bone mass Weight bearing Exercise		
Hypomagnesemia	Re-evaluate need Limit dose and duration Consider baseline testing (diuretics, digoxin) Supplementation		
Clostridium difficle associated diarrhea	Re-evaluate need Limit dose and duration Evaluate for C. difficle if patient receiving PPI has diarrhea that is not improving. Have patients report diarrhea. Report cases to Medwatch		

Patient Case # 1

- Which one of the following baseline tests is best to perform in this patient today before initiating his esomeprazole therapy?
 - A. Peripheral bone mineral density screening.

B. Serum magnesium.

- C. Serum potassium.
- D. Chest radiograph.

Handout Page 1-81; Answer Page 1-137

Patient Case # 2

- HPI: 68 year old female with heme positive stools anemia and abdominal pain. Use of OTC ketoprofen for 2 months.
- PMH: Type 2 DM, Peripheral neuropathy, Hypertension
- MEDS: metformin, aspirin, gabapentin, lisinopril
- Diagnostics: endoscopy reveals 1 cm gastric ulcer with an intact clot, *H. pylori* negative via CLO Test

Handout Page 1-87; Answer Page 1-137

Patient Case # 2

- Which one of the following treatments is best for this patient's ulcer?
- A. Ranitidine 150 mg 2 times/day for 4 weeks
- B. Lansoprazole 30 mg 2 times/day plus amoxicillin 1000 mg 2 times/day plus clarithromycin 500 mg 2 times/day for 10 days.
- C. Lansoprazole 30 mg/day for 8 weeks
- D. Misoprostol 200 mcg 4 times/day for 8 weeks.

Handout Page 1-87; Answer Page 1-137

Peptic Ulcer Disease (PUD)

- Classification
 Duodenal ulcer
 - Gastric ulcer
- Etiologies
 - Helicobacter pylori (carcinogen)
 - NSAIDs
- Symptoms
 - Epigastric pain, nausea, anorexia, belching
 - May be temporally related to food intake

NSAID Associated PUD

- NSAIDs have topical and systemic adverse GI effects
 COX-2 vs. COX-1 effects
- Risk Factors
 - □ Age >60, History of PUD +/- complications
 - $\hfill\square$ Corticosteroids, anticoagulants, low dose aspirin, aspirin, \uparrow NSAID dose
- Contributing factors
 - □ H. pylori, Smoking, CVD, RA, SSRIs

Management of NSAID-Associated PUD

- Remove and reevaluate need for NSAID and/or aspirin
 - □ Test for *H. pylori* and treat if positive
- Acid suppression
 PPI for 8-12 weeks
- Misoprostol
- COX-2 Inhibitors
- Cardiovascular risks
- Use with aspirin

Patient Case # 2 Which one of the following treatments is best for this patient's ulcer? A. Ranitidine 150 mg 2 times/day for 4 weeks B. Lansoprazole 30 mg 2 times/day plus amoxicillin 1000 mg 2 times/day plus clarithromycin 500 mg 2 times/day for 10 days. C. Lansoprazole 30 mg/day for 8 weeks D. Misoprostol 200 mcg 4 times/day for 8 weeks. Handout Page 1-87; Answer Page 1-137

Patient Case #3

- HPI: 42 year old male with sharp epigastric pain for 6 weeks. Pain is worse with eating and is present approximately 5 days per week. Some relief with OTC antacids.
- MEDS: antacids as needed
- Allergies: Penicillin (severe rash)
- UBT for *H. pylori* is positive

Handout Page 1-87; Answer Page 1-137

Patient Case #3

- Which one of the following treatments for *H. pylori* is best?
- A. Amoxicillin, clarithromycin, omeprazole for 10 days
- B. Cephalexin, clarithromycin, omeprazole for 10 days
- c. Bismuth, tetracycline, metronidazole, omeprazole for 14 days
- D. Levofloxacin, metronidazole, omeprazole for 10 days

Handout Page 1-87; Answer Page 1-137

Diagnosis of H. pylori

- Invasive testing (endoscopic)
 - Histology
 - □ Rapid urease (affected by antisecretory agents)
 - □ Culture
- Non-invasive testing
 - □ Serologic (IgG)
 - Urea breath test (affected by antisecretory agents)
 - □ Fecal antigen (affected by antisecretory agents)

Treatment of H. pylori

- Triple therapy
 - □ PPI + amoxicillin or metronidazole + clarithromycin
 - □ 10-14 days of treatment (14 preferred)
 - □ Efficacy affected by previous macrolide exposure
- Quadruple Therapy
 - □ PPI + Bismuth + Metronidazole + Tetracycline
 - Ist line, PCN allergy, previous macrolide exposure, failure of triple therapy
 - □ 10-14 days of treatment

Patient Case #3

• Which one of the following treatments for *H. pylori* is best?

Amoxicillin, clarithromycin, omeprazole for 10 days

Cephalexin, clarithromycin, omeprazole for 10 days

Bismuth, tetracycline, metronidazole, omeprazole for 14 days

Levofloxacin, metronidazole, omeprazole for 10 days

Handout Page 1-87; Answer Page 1-137

Patient Case #4

- HPI: 35 year old male with ulcerative colitis (majority of colon). Experiences 5-6 bloody bowel movements per day when prednisone is reduced to less than 40mg/day.
- MEDS: Balsalazide 6.75 g/day x 2 years, prednisone 40 mg/day x 1 year

Handout Page 1-100; Answer Page 1-137

Patient Case #4

- What would be an appropriate modification of his drug regimen at this time?
- A. Change balsalazide to sulfasalazine 6g/day
- B. Initiate therapy with methotrexate IM weekly
- c. Initiate infliximab and taper prednisone
- D. Add mesalamine suppository daily

Handout Page 1-100; Answer Page 1-137

Clinical Findings	Ulcerative Colitis	Crohn's Disease
Bowel Involvement	Rectum/Colon	Mouth to Anus
Perianal Involvement	No	Yes
Depth	Superficial	Submucosa/deeper
Pattern of inflammation	Continuous	Patchy
Histology	Crypt abscesses	Granulomas
Fistula, perforation, or	No	Yes
Strictures		
Toxic megacolon	Yes	No
Colorectal cancer	Yes	Uncommon
Malnutrition	Rare	Yes
Pseudopolyps	Common	Fairly Common


Drug Treatmen	nt Options
 5-Aminosalicylates Sulfasalazine Mesalamine Olsalazine Balsalazide Antibiotics Metronidazole Ciprofloxacin Corticosteroids 	 Immunomodulators Azathioprine 6-Mercaptopurine Methotrexate Cyclosporine Tacrolimus Biologics Infliximab Adalimumab Certolizumab Natalizumab

Approach to the Treatment of IBD

- 1. Indentify disease: UC vs. CD
- 2. Severity: Active (mild to fulminant) or remission
- 3. Determine extent and location of disease

4. Pick drug(s) based on

- Onset of action
- □ Formulation (Oral, Topical, Parenteral)
- Effectiveness
- Potential adverse effects or contraindications




Drug(s)	Adverse Effects		
TNF-alpha antagonists	Risk of infection (screen for TB and Viral hepatitis) Risk of Heart Failure and/or exacerbation Hepatosplenic Tccell lymphoma when used with azathioprine or 6-MP in young male patients Antibody formation		
Antimotility agents	Risk of toxic megacolon in active disease		
Azathioprine/6MP	Bone marrow suppression, pancreatitis, hypersensitivity Need to check TPMT activity		
Methotrexate	Bone marrow suppression, pulmonary and hepatic toxicity		
Corticosteroids	Adrenal suppression, metabolic effects, infection		
Natalizumab	Progressive mutilfocal leukoencephalopathy		

Patient Case #4 What would be an appropriate modification of his drug regimen at this time? Change balsalazide to sulfasalazine 6g/day Initiate therapy with methotrexate IM weekly Initiate infliximab and taper prednisone Add mesalamine suppository daily Handout Page 1-100; Answer Page 1-137

Patient Case #5 HPI: 25 year old woman with Crohn's disease. Presents with a 2 day history of crampy abdominal pain, fever, fatigue, and 10-12 bloody stools per day.

- MEDS: Pentasa 250mg #4 caps 2 times/day
- PMH: Crohn's Disease x 5 years
- Vitals: Temp 101F, HR=110, RR=18, BP = 118/68

Handout Page 1-100; Answer Page 1-138



Patient Case #6


- HPI: 47 year old woman with nausea, abdominal pain, fever. Abdominal distention with tenderness and shifting dullness.
- PMH: Cirrhosis (Class C)
- MEDS: Furosemide, spironolactone
- Diagnostics: Paracentesis (albumin 0.9 g/dl, WBC 1000/mm³)


Handout Page 1-107; Answer Page 1-138

Patient Case #6

- Which recommendation is best at this time for treatment of this patient's hepatic encephalopathy?
- A. Intravenous albumin
- B. Intravenous vancomycin plus tobramycin
- c. Intravenous cefotaxime plus albumin
- D. Oral trimethoprim/sulfamethoxazole DS daily

Handout Page 1-107; Answer Page 1-138





SBP Treatment and Prevention

- Treatment: 3rd gen Cephalosporin + albumin
- Primary Prevention
 - During setting of an acute GI bleed
 - Ascitic fluid protein < 1.5 g/dl + Scr > 1.2 mg/dl or BUN > 25 mg/dl or Na < 130 mEq/L, or CP > 9 with bilirubin > 3 mg/dl
- Secondary Prevention: any patient with prior episode
- Hospital: Ceftriaxone/Cefotaxime, Fluoroquinolone
- Outpatient: TMP/SMX, Norfloxacin/ciprofloxacin

Patient Case #6 • Which recommendation is best at this time for treatment of this patient's SBP? • Intravenous albumin • Intravenous vancomycin plus tobramycin • Intravenous cefotaxime plus albumin • Oral trimethoprim/sulfamethoxazole DS daily • Handout Page 1-107; Answer Page 1-138

Patient Case #7

- HPI: 36 year old female with 36 hours of hematemesis, fatigue, dizziness, black tarry stools.
- PMH: Cirrhosis, alcohol abuse, MI (2 years ago)
- Diagnostics: EGD several large esophageal varices that are banded.

Handout Page 1-107; Answer Page 1-138

Patient Case #7

- In addition to the endoscopic band ligation which of the pharmacologic interventions is best?
- A. Nadolol 20mg orally once a day x 3 days
- B. Vasopressin continuous infusion x 2 days
- c. Octreotide 50 ug bolus, then 50 ug/hr for 5 days
- D. Pantoprazole 80mg bolus, then 8mg/hr x 72 hours

Handout Page 1-107; Answer Page 1-138

Variceal Bleeding

- Varices: Collateral vessels formed secondary to increased resistance to blood flow within the liver
- Bleeding risk
 - □ 25-35% of patient with cirrhosis
 - □ 30-50% mortality per bleed
- High recurrence rate
 ~70% within first month of bleed

Treatment of Variceal Bleeding


- Stabilization + IV fluids
- Endoscopic interventions
 - □ Sclerotherapy
 - Band ligation
- Medical Management
 - Vasopressin + nitroglycerin
 - Octreotide x 3-5 days
 - □ Antibiotics (3rd Gen Ceph or Fluoroquinolone)

Prevention of Variceal Bleeding

- Pharmacologic +/- endoscopic
- Primary prevention
 - Small varices + high bleeding risk
 - Medium/Large varices
 - Non selective beta blockers
- Secondary prevention
 - □ All patients with history of bleeding
 - Non selective beta blockers
 - Endoscopic (band ligation)

Patient Case #7

• In addition to the endoscopic band ligation which of the pharmacologic interventions is best?



Vasopressin continuous infusion x 2 days

Octreotide 50 ug bolus, then 50 ug/hr for 5 days

Pantoprazole 80mg bolus, then 8mg/hr x 72 hours

Handout Page 1-107; Answer Page 1-138

Patient Case #8

- HPI: 45-year old woman with history of IVDA. Diagnosed 8 months ago with HBV. Treatment naive. No ascites or encephalopathy.
- Diagnostics:
 - □ AST 650 IU/ml, ALT 850 IU/ml
 - □ HBSAg (+), HBeAg (+), YMDD mutation
 - $\square~$ HBV DNA 107, 000 IU/ml
 - □ Biopsy: severe necroinflammation/bridging fibrosis

Handout Page 1-121; Answer Page 1-138

Patient Case #8

- What is the most appropriate course of action at this time?
- A. No treatment; Recheck HBV DNA in 6 months
- в. Initiate PEG-IFN + ribavirin
- c. Initiate lamivudine 100 mg/day
- D. Initiate tenofovir 300 mg/day

Handout Page 1-121; Answer Page 1-138

Hepatitis B

- DNA Virus, Genotypes A-H
- Transmission
 Parenteral, bodily fluids, sexual contact, perinatal
- Detect via serologies, symptoms, LFTs
 Patients with active disease will be HBsAg (+)
- Treat patients with chronic disease (> 6 months)
 > 2 x ALT, HBV DNA > 20,000 IU/ml

Chronic Hepatitis B Treatment

- Need to distinguish if HBV:
 - · is HBeAg positive or negative
 - Harbors the "YMDD mutation" of the DNA polymerase
- Difficult patient populations
 - · Decompensated liver disease
 - •Co-infection
 - Treatment experienced

HBV Population	Preferred Treatment Options	Duration	Comments
HBeAg positive	Entecavir and tenofovir are preferred oral agents Use of the other oral reverse transcriptase inhibitors is possible but not preferred	Minimum of 1 year	Preferred if contraindications or · nonresponse to INFα
	INFα PEG-INFα	16 weeks 48 weeks	If contraindication or no response, use entecavir and tenofovir
HBeAg negative	Entecavir and tenofovir are preferred oral agents Use of the other oral reverse transcriptase inhibitors is possible but not preferred	> 1 year	Preferred if contraindications or no response to INFα
	INFα PEG-INFα	≥ 1 year	If contraindication or nonresponse, use entecavir and tenofovir

Nucleoside Analog Adverse Effects

- Class effects
- Rebound hepatitis upon discontinuation
- GI Effects (N/V/D/Abdominal pain)
- HIV resistance
 Lactic Acidosis (rare)
- Lactic Acidosis (rare)
 Reductions in bone mineral density
- Nephrotoxicity (adefovir)
- Telbivudine
 Elevations in CK
- Elevations in CK
 Peripheral neuropathy
- Renally dose all medications

Patient Case #8

• What is the most appropriate course of action at this time?

No treatment; Recheck HBV DNA in 6 months

Initiate PEG-IFN + ribavirin

Initiate lamivudine 100 mg/day

Initiate tenofovir 300 mg/day

Handout Page 1-121; Answer Page 1-138

Patient Case #9

- HPI: 38 year old male with chronic hepatitis C (genotype 1) currently undergoing treatment Evaluated at 12 week follow up appointment after starting treatment.
- MEDS: Pegylated interferon + ribavirin
- LABS:
 AST 90 IU/ml (350 IU/ml), ALT 64 IU/ml (420 IU/ml)
 HCV RNA 3500 IU/ml (450,000 IU/ml)

Handout Page 1-121; Answer Page 1-138

Patient Case #9

- What is the most appropriate course of action at this time?
- A. Discontinue therapy and monitor for symptoms
- B. Continue treatment for an additional 12 weeks
- c. Add boceprevir for an additional 12 weeks
- D. Continue treatment for an additional 72 weeks

Handout Page 1-121; Answer Page 1-138

Hepatitis C

- RNA Virus
 - Genotypes 1-6 (1-3 most common is US)
 Several subtypes
 - Genotype 1 most resistant to drug treatment
 - Transfusion, IV drug abuse, transplant
- Major cause of chronic liver disease
 60-80% progression following acute infection
 - □ #1 reason for transplant

Treatment of Chronic Hepatitis C

- First line:
 - Genotype 1 :Pegylated interferon + ribavirin + telaprevir OR boceprevir
 - Genotypes 2 and 3 :Pegylated interferon + ribavirin

Pegylated Interferon Dosing:

- Degasys: 180ug SQ Weekly
- □ Peg Intron: 1-1.5 ug/kg/week SQ
- Ribavirin orally in 2 divided doses:
- Dose differs based on genotype, weight, and interferon product

Direct Acting Antivirals (DAAs)

	Telapravir (Incivek®)	Boceprevir (Victrelis®)
FDA Approved indication	Chronic HCV therapy (genotype 1) in <u>combination</u> with PEG-INf affa and ribavirin in patients with compensated liver disease	 chronic HCV genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (≥18 years of age) with compensated liver disease, including cirrhosis, who are
	Not studied in Child-Pugh class B or C	previously untreated or who have failed previous interferon and ribavirin therapy.

Direct Acting Antivirals (DAAs)


		Telapravir (Incivek®)		Boceprevir (Victrelis®)
Dose	•	750 mg three times daily for 12 weeks followed by PEG-INF and ribavirin x 12 weeks if undetectable HCV RNA at week 4 and 12.	•	800 mg orally three times daily starting after 4 weeks of PEG-INF and ribavirin
	•	375 mg tablets	·	200 mg capsules
	•	Give doses 7-9 hours apart; give with meal that has at least 20 g fat ingested 20 minutes prior	•	Give doses 7-9 hours apart; give with meal or light snack
	•	Take missed doses if within 4 hours	•	Take missed doses if within 2 hours


DAA Safety

Both contraindicated in pregnancy and in male partners of pregnant women


Telaprevir

- □ Rash (up to 56%) maculopapular/eczematous
- DRESS, Stevens Johnson Syndrome
- Anemia, pruritis, nausea
- Boceprevir
 - Anemia, neutropenia, fatigue, dysgeusia







Parameter	Definition
Rapid Virological Response (RVR)	Negative HCV RNA at week 4 of treatment
Early Virological Response (EVR)	> 2 log decline in HCV RNA compared to baseline or negative HCV RNA at 12 weeks
End of Treatment Response (ETR)	Negative HCV RNA at the end of a 24 or 48 week course depending on genotype
Sustained Virological Response (SVR)	Negative HCV RNA 24 weeks after finishing treatment



Regimen	Patient Group	HCV RNA Week 4	HCV RNA Week 8	Recommendation
PEG-INF+	Previously	Undetectable	Undetectable	Continue all 3 drugs for 28 weeks total
Ribavirin + Boceprevir	untreated	Detectable	Undetectable	 Continue all 3 drugs for a total of 36 weeks. Then continue PEG-INF and ribavirin for through week 48
Previous partial responders or relapsers	Previous partial	Undetectable	Undetectable	Continue all 3 drugs for 36 weeks total
	Detectable	Undetectable	 Continue all 3 drugs for a total of 36 weeks. Then continue PEG-INF and ribavirin for through week 48 	
	Patients with HCV RNA > 100 IU/ml at week 12 or detectable HCV RNA at week 24	NA	NA	1. Discontinue all 3 drugs






Patient Case #10

- HPI: 55 year old man with chronic alcohol abuse and chronic pancreatitis. Steatorrhea and weight loss (now 135 lb)
- LABS: Albumin 2.1 g/dl, Fecal fat 20g/day
- Medications: morphine CR, oxycodone IR as needed


Handout Page 1-134; Answer Page 1-139



Acute Pancreatitis

- Largely supportive Care
- Pain management
- Antiemetics
- Nutritional support
 - Enteral
 - Hyperglycemia
- Antibiotics
 - □ Infection, abscess, or necrosis

Complication	Targeted Therapies	Comments	
Pain	Narcotic +/ non-	 Acetaminophen and/or NSAIDs 	
	narcotic therapies	 Long acting narcotic preparations + IR breakthrough 	
	Pancreatic enzymes	 Caution with acetaminophen and narcotics if alcohol use is continued 	
Maldigeston and Malabsorption	Pancreatic enzymes	• Start around 30,000-40,000 lipase units per meal; ^{1/2} dose for snacks	
		 Do not crush or chew 	
		 Max 2500 u/kg/dose; 10,000 u/kg/day 	
		 Titrate to steatorrhea + weight gain 	
		 Porcine based so avoid if pork allergy 	
	Fat soluble vitamins	• ADEK	
Diabetes	Insulin	Long acting + short acting	
		 Oral intake may be variable 	



Patient Case #11

- HPI: 32 year old woman with crampy abdominal pain, bloating and constipation for 6 months. Not food related. Diagnosed with IBS-C.
- LABS: within normal limits
- Medications and allergies: none

Handout Page 1-134; Answer Page 1-139

Patient Case #11


- A. Which of the following therapeutic interventions is best for this patient?
- B. Amitriptyline 50 mg/day
- c. Senna 2 tablets twice daily
- D. Tegaserod 6 mg twice daily
- D. Lubiprostone 8 mcg twice daily

Handout Page 1-134; Answer Page 1-139

Irritable bowel syndrome

- Categories
 - Diarrhea Predominant (IBS-D)
 - □ Constipation Predominant (IBS-C)
 - Mixed Pattern (IBS-M)
- Features
 - □ Change in frequency and/or stool appearance
 - De Pain, bloating, Relief with defecation
- Target main symptoms and comorbidities

Therapies	Comments
Hyoscyamine, dicyclomine	Target pain due to spasm and also treat diarrhea Initial or adjunctive therapy for IBS-D or IBS-M
Tricyclic antidepressants	Target pain and diarrhea Generally reserved for IBS-D Low doses
SSRIs, SNRIs	Target pain and often have promotility action in IBS-D Can also treat comorbid depression and anxiety
Lubiprostone	Indicated for IBS-C in women > 18 years Main adverse effect is nausea, more expensive option
Loperamide	Adjunctive for IBS-D, but does not treat pain
Probiotics	Some potential improvement in global symptoms and pain
Alosetron Indicted for IBS-D in women > 18 years failing other therapies • Must be enrolled in prescribing program • Risk of ischemic colitis	
Tegaserod	• Indication: IBS-C; available on emergency use only due to CV risk
Rifaximin	Some data to support improvement in bloating



Patient Case #12

- HPI: 30 year old pregnant woman (14 weeks) with myalgias, watery diarrhea (4-5), vomiting x 1.
- LABS: influenza (-), WBC 8000 x 10³
- Medications: prenatal vitamin
- Allergies: none

Handout Page 1-134; Answer Page 1-139

Patient Case #12


- What is the most appropriate course of action at this time for this patients diarrhea?
- A. Loperamide
- в. Bismuth subsalicylate
- c. Lactase
- D. Pyridoxine

Handout Page 1-134; Answer Page 1-139

Management of Diarrhea

- Remove correct underlying cause
 Identify drug-induced causes
- Rehydration
 - □ ORS
 - Parenteral
- Dietary modification

Therapies	Comments		
Loperamide	• OTC and prescription products, tablet and liquid • OTC indicated in age > 6 • Pregnancy category B		
Opioids (diphenoxylate, tincture of opium)	Generally reserved for more severe cases Increased risk of CNS adverse effects		
Bismuth subsalicylate	OTC tablet and liquid preparations Avoid: Patients < 12 years of age Pregnancy Salicylate allergy Signs/symptoms of bleeding or mucous Stool and tongue discoloration Chelation interactions		
Lactase	Suspected or diagnosed lactose intolerance		
Probiotics	Data in AAD, IBD, IBS, radiation induced		



• What is the most appropriate course of action at this time for this patients diarrhea?

Loperamide

Bismuth subsalicylate

Lactase

Pyridoxine

Handout Page 1-134; Answer Page 1-139

